New hope for Tough-to-Treat breast cancer: can a drug combo outperform a single pill?
NCT ID NCT06062498
Summary
This study is for people with advanced or metastatic breast cancer that is estrogen-receptor-positive and HER2-negative, and whose cancer has grown despite prior treatments including a specific type of targeted drug (a CDK4/6 inhibitor). It aims to find out if taking the drug elacestrant alone works as well as taking elacestrant combined with a different CDK4/6 inhibitor. The main goal is to see which approach better controls the cancer and prevents it from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.